Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2014
03/06/2014WO2014035356A1 Tablet formulations comprising a quinone derivative active agent
03/06/2014WO2014035355A1 Pharmaceutical combination comprising idebenone and memantine
03/06/2014WO2014035295A1 Pharmaceutical composition for treating gastro-oesophageal reflux disease
03/06/2014WO2014035246A1 Antimicrobial composition
03/06/2014WO2014035214A1 Composition comprising amorpha fruticosa extracts
03/06/2014WO2014035190A1 Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor
03/06/2014WO2014035188A1 Bilayered composite tablet formulation comprising atorvastatin, irbesartan and magnesium carbonate
03/06/2014WO2014035149A1 N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug
03/06/2014WO2014035070A1 Composition for preventing or treating kidney disease comprising pyrazole derivative
03/06/2014WO2014035064A1 The novel tenofovir disoproxil salt and the preparation method thereof
03/06/2014WO2014034939A1 Adhesive skin patch
03/06/2014WO2014034934A1 Oligonucleotide
03/06/2014WO2014034929A1 Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition
03/06/2014WO2014034902A1 Amine salt and crystals thereof
03/06/2014WO2014034898A1 Pyridine derivative and medicine
03/06/2014WO2014034890A1 Method for administering hypnotic/sedative agent
03/06/2014WO2014034871A1 Drug for preventing or treating dyslipidemia
03/06/2014WO2014034860A1 Orally administered medical composition
03/06/2014WO2014034842A1 Combination of sglt2 inhibitor and anti-hypertension drug
03/06/2014WO2014034798A1 Method for detection of cancer, diagnostic drug and diagnostic kit for cancer, and pharmaceutical composition for treatment of cancer
03/06/2014WO2014034756A1 Pharmaceutical composition for use in treatment of status epilepticus
03/06/2014WO2014034751A1 Endoparasite control agent and use thereof
03/06/2014WO2014034750A1 Endoparasite control agent
03/06/2014WO2014034719A1 Quinoline derivative having tlr inhibitory activity
03/06/2014WO2014034626A1 CRYSTAL OF N-[2-({2-[(2S)-2-CYANOPYRROLIDIN-1-YL]-2- OXOETHYL}AMINO)-2-METHYLPROPYL]-2-METHYLPYRAZOLO[1,5-a]PYRIMIDINE-6-CARBOXAMIDE
03/06/2014WO2014034147A1 Trehangelin compounds as novel photosensitivity inhibitors and method for producing same
03/06/2014WO2014033744A2 A novel pharmaceutical composition of linezolid
03/06/2014WO2014033680A1 Gelling formulation containing ketamine
03/06/2014WO2014033668A2 Combination of a macrocyclic protease inhibitor of hcv, a non-nucleoside hcv inhibitor and ritonavir
03/06/2014WO2014033654A1 Salts of benzothiazolone compound as beta-2-adrenoceptor agonist
03/06/2014WO2014033631A1 N-(3-pyridyl) biarylamides as kinase inhibitors
03/06/2014WO2014033630A1 Novel aminothiazole carboxamides as kinase inhibitors
03/06/2014WO2014033604A1 Arylalkylamine compounds as calcium sensing receptor modulators
03/06/2014WO2014033597A1 5-azaindole compounds with anticancer and antiangiogenic activities
03/06/2014WO2014033561A1 Antibacterial compositions
03/06/2014WO2014033560A1 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
03/06/2014WO2014033551A2 The use of direct thrombin inhibitors in critically ill patients
03/06/2014WO2014033530A1 1,3-dioxanomorphides and 1,3-dioxanocodides
03/06/2014WO2014033526A1 Pharmaceutical compositions of etoricoxib
03/06/2014WO2014033497A1 5-azaindole compounds with anticancer and antiangiogenic activities
03/06/2014WO2014033490A1 Preventive products against pathogenic germs, and method for use thereof
03/06/2014WO2014033480A1 Histamine 4 receptor partial agonists, inverse agonists or antagonists for use|in treating non-autoimmune uveitis
03/06/2014WO2014033477A1 Pyridinone compounds for use in photodynamic therapy
03/06/2014WO2014033449A1 Kinase inhibitors
03/06/2014WO2014033448A1 Pyrazole derivatives as p38 map inhibitors
03/06/2014WO2014033446A1 Kinase inhibitors
03/06/2014WO2014033368A1 Composition for tissue repair and regeneration
03/06/2014WO2014033366A1 Pharmaceutical compositions of anisomelic acid and the use thereof
03/06/2014WO2014033346A1 System for transporting biologically active molecules, comprising a nanoparticle, a peptide and a biologically active molecule
03/06/2014WO2014033343A1 Beta-3 adrenoceptor agonists for the treatment of pulmonary hypertension
03/06/2014WO2014033314A1 Antisense oligonucleotide targeting bacterial glucosyltransferases
03/06/2014WO2014033298A2 Modulating transendothelial migration and recruitment of granulocytes by modulating c-met pathway
03/06/2014WO2014033291A1 Pharmaceutical compositions comprising an active agent
03/06/2014WO2014033262A1 Therapeutic and diagnostic mirna regulator in kidney disease
03/06/2014WO2014033230A1 Compositions for oral administration to animals, production methods thereof and uses of same
03/06/2014WO2014033221A1 Otamixaban for use in the treatment of non-st elevation acute coronary syndrome in patients planned to undergo coronary artery bypass grafting
03/06/2014WO2014033196A1 Dioxino- and oxazin-[2,3-d]pyrimidine pi3k inhibitor compounds and methods of use
03/06/2014WO2014033176A1 Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
03/06/2014WO2014033170A1 Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
03/06/2014WO2014033167A1 Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis b
03/06/2014WO2014033136A1 Aminoheteroaryl compounds as mth1 inhibitors
03/06/2014WO2014033077A1 Composition comprising an antibiotic and a beta-lactamase inhibitor, wherein at| least one of them is in the form of mini-tablets
03/06/2014WO2014032801A1 Fluoromethyl-substituted pyrrole carboxamides
03/06/2014WO2014032780A1 Hybrid hydrogels
03/06/2014WO2014032755A2 Ddr2 inhibitors for the treatment of osteoarthritis
03/06/2014WO2014032742A1 Pharmaceutical or nutraceutical composition with sustained release characteristic and with resistance against the influence of ethanol
03/06/2014WO2014032741A1 Gastric resistant pharmaceutical or nutraceutical composition with resistance against the influence of ethanol
03/06/2014WO2014032735A1 Use of 3-(2,2,2-trimethylhydrazinium)-ethylpropionate or a pharmaceutically acceptable salt for treating high tension glaucoma
03/06/2014WO2014032732A1 Halogenated benzoxazines and use thereof
03/06/2014WO2014032696A1 Virucidal composition
03/06/2014WO2014032583A1 Selenazole formic acid type compound and preparation method and use thereof
03/06/2014WO2014032498A1 Highly selective c-met inhibitors as anticancer agents
03/06/2014WO2014032481A1 Tenofovir prodrug and pharmaceutical uses thereof
03/06/2014WO2014032398A1 Pyridazinone compound, preparation method, pharmaceutical composition and use thereof
03/06/2014WO2014032188A1 Glycosidase inhibitors and uses thereof
03/06/2014WO2014032187A1 Glycosidase inhibitors and uses thereof
03/06/2014WO2014032185A1 Glycosidase inhibitors and uses thereof
03/06/2014WO2014032184A1 Glycosidase inhibitors and uses thereof
03/06/2014WO2014032183A1 Dihydrochalcone derivatives and their use as antibiotic agents
03/06/2014WO2014032176A1 Methods for the treatment of hepatitis b and hepatitis d infections
03/06/2014WO2014032152A1 Polymeric finasteride and minoxidil nanoparticles, method for preparing same, aqueous suspension containing same, pharmaceutical composition and use thereof
03/06/2014WO2014032151A1 Polymeric finasteride nanoparticle, aqueous composition containing same, composition for the treatment of alopecia, method for preparing said composition, and use thereof
03/06/2014WO2014032108A1 Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditions
03/06/2014WO2014032099A1 Composition and method for bone growth
03/06/2014WO2014015235A3 3,5,n-trihydroxy-alkanamide and derivatives: method for making same and use thereof
03/06/2014WO2014012094A3 Tetracycline compounds for treating neurodegenerative disorders
03/06/2014WO2014012081A3 Chiral control
03/06/2014WO2014012075A3 Treating hair loss and delaying aging of skin
03/06/2014WO2014011083A3 Pharmaceutical composition having improved flowability, medicinal agent, and method for producing and using same
03/06/2014WO2014011077A3 Pharmaceutical composition having a metabolic, anti-cataract, retina-protecting effect (variants)
03/06/2014WO2014010654A3 Sulfonamide compound combination
03/06/2014WO2014009966A3 An improved process for the preparation of dabigatran etexilate mesylate and its intermediates thereof
03/06/2014WO2014009808A3 Lipidated peptides as anti-obesity agents
03/06/2014WO2014008838A4 Bis-indolylacetic acid derivative attached with aryl substituted methyl, and preparation method and use thereof
03/06/2014WO2014008353A3 Compositions comprising sulforaphane or a sulforaphane precursor and a mushroom extract or powder
03/06/2014WO2014007951A3 Substituted tricyclic compounds as fgfr inhibitors
03/06/2014WO2014006569A3 Saxagliptin salts
03/06/2014WO2014004902A3 Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof
03/06/2014WO2013190510A3 NOVEL 2,3-DIHYDRO-1H-IMIDAZO{1,2-a}PYRIMIDIN-5-ONE and this1,2,3,4-TETRAHYDROPYRIMIDO{1,2-a}PYRIMIDIN-6-ONE DERIVATIVES COMPRISING A SUBSTITUTED MORPHOLINE, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF
03/06/2014WO2013186777A3 Use of blocking agents of bone morphogenie protein (bmp) signaling for the treatment of neuroinflammatory and neurodegenerative diseases
1 ... 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 ... 7860